



FW

PATENT
ATTORNEY DOCKET NO. 01948/095002

Certificate of Mailing: Date of Deposit: January 13, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Alexis L. Perry

Printed name of person mailing correspondence

[Signature]
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|---|---------------|------------------|
| Applicant: | Robson et al. | Art Unit: | 1614 |
| Serial No.: | 10/820,335 | Examiner: | Not yet assigned |
| Filed: | April 8, 2004 | Customer No.: | 21559 |
| Title: | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING AUTOIMMUNE DISORDERS | | |

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

January 13, 2006



Kristina Bieker-Brady, Ph.D., P.C.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 2

| | | | | | | | |
|--|--------------------|---------------------|-----------------------------|--|----------|---|--|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) | | | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | Attorney Docket No. 01948/095002 Serial No. 10/820,335 Applicant Robson et al. Filing Date April 8, 2004 Group 1614 IDS Filed January 13, 2006 Customer No. 21559 | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | | | | |
| (37 C.F.R. §1.98(b)) | | | | | | | |
| U.S. PATENTS | | | | | | | |
| Examiner's Initials | Patent Number | Issue Date | Patentee | Class | Subclass | Filing Date (If Appropriate) | |
| | | | | | | | |
| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | | | | |
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) | |
| | WO 00/23459 | 04/27/00 | WIPO | | | | |
| | WO 03/052121 | 06/26/2003 | WIPO | | | | |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | | | | | | | |
| Eltzschig et al., "Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium: Role of Ectonucleotidases and Adenosine A _{2B} Receptors," <i>J. Exp. Med.</i> 198:783-796 (2003). | | | | | | | |
| Enjoji et al., "Targeted Disruption of cd39/ATP Diphosphohydrolase Results in Disordered Hemostasis and Thromboregulation," <i>Nat. Med.</i> 5:1010-1017 (1999). | | | | | | | |
| Gangadharan et al., "Targeting Platelet Aggregation: CD39 Gene Transfer Augments Nucleoside Triphosphate Diphosphohydrolase Activity in Injured Rabbit Arteries," <i>Surgery</i> 130:296-303 (2001). | | | | | | | |
| Goepfert et al., "CD39 Modulates Endothelial Cell Activation and Apoptosis," <i>Mol. Med.</i> 6:591-603 (2000). | | | | | | | |
| Goepfert et al., "Disordered Cellular Migration and Angiogenesis in cd39-Null Mice," <i>Circulation</i> 104:3109-3115 (2001). | | | | | | | |
| Hall et al., "A C-Terminal Motif Found in the β ₂ -Adrenergic Receptor, P2Y ₁ Receptor and Cystic Fibrosis Transmembrane Conductance Regulator Determines Binding to the Na ⁺ /H ⁺ Exchanger Regulatory Factor Family of PDZ Proteins," <i>Proc. Natl. Acad. Sci. USA</i> 95:8496-8501 (1998). | | | | | | | |
| Imai et al., "Suppression of ATP Diphosphohydrolase/CD39 in Human Vascular Endothelial Cells," <i>Biochemistry</i> 38:13473-13479 (1999). | | | | | | | |
| Kegel et al., "An Ecto-ATPase and an Ecto-ATP Diphosphohydrolase are Expressed in Rat Brain," <i>Neuropharmacology</i> 36:1189-1200 (1997). | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | | | | | | | |

Sheet 2 of 2

| | | | |
|---|---|---------------------|------------------|
| SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE | | Attorney Docket No. | 01948/095002 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | Serial No. | 10/820,335 |
| | | Applicant | Robson et al. |
| | | Filing Date | April 8, 2004 |
| | | Group | 1614 |
| | | IDS Filed | January 13, 2006 |
| (37 C.F.R. §1.98(b)) | | Customer No. | 21559 |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | | | |
| | Koziak et al., "Palmitoylation Targets CD39/Endothelial ATP Diphosphohydrolase to Caveolae," <i>J. Biol. Chem.</i> 275:2057-2062 (2000). | | |
| | Laemmli, "Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4," <i>Nature</i> 227:680-685 (1970). | | |
| | Mizumoto et al., "CD39 is the Dominant Langerhans Cell-Associated Ecto-NTPDase: Modulatory Roles in Inflammation and Immune Responsiveness," <i>Nat. Med.</i> 8:358-365 (2002). | | |
| | Robson et al., "Modulation of Extracellular Nucleotide-Mediated Signaling by CD39/Nucleotide Triphosphate Diphosphohydrolase-1," <i>Drug. Dev. Res.</i> 53:193-207 (2001). | | |
| | Sévigny et al., "Purification of the Blood Vessel ATP Diphosphohydrolase, Identification and Localisation by Immunological Techniques," <i>Biochim. Biophys. Acta.</i> 1334:73-88 (1997). | | |
| EXAMINER | | DATE CONSIDERED | |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | | | |